Creatine Kinase Brain Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Protein Name | Creatine Kinase Brain (CK-BB) |
|---|
| Gene | CKB |
|---|
| UniProt ID | P12277 |
|---|
| PDB IDs | 1I0Z, 2CRK, 3B6R |
|---|
| Molecular Weight | 43 kDa |
|---|
| Subcellular Localization | Cytoplasm, Mitochondria (outer membrane) |
|---|
| Protein Family | Creatine kinase family |
|---|
Brain-type creatine kinase (CK-BB, CKB) is a key enzyme in the phosphocreatine (PCr) energy shuttle system. It catalyzes the reversible transfer of a phosphate group from phosphocreatine to ADP, maintaining cellular energy homeostasis, especially in tissues with high and fluctuating energy demands like the brain.
Creatine kinase is a homodimer:
- Monomer (~43 kDa):
- N-terminal domain: Substrate binding
- C-terminal domain: Catalytic site
- Flexible loops for substrate access
Phosphocreatine + ADP ↔ Creatine + ATP
- Forward reaction: Recharges ATP from PCr
- Reverse reaction: Generates PCr when ATP is abundant
- ATP Buffering: Maintains ATP levels during demand spikes
- PCr Shuttle: Spatial energy transport from mitochondria to cytosol
- Rapid Response: Near-instantaneous energy delivery
- pH Buffer: PCr helps buffer cellular pH
- Supports synaptic vesicle cycling
- Powers ion pumps (Na+/K+ ATPase)
- Enables action potential generation
- Protects against oxidative stress
- Supports long-term potentiation
- CKB activity significantly reduced in AD brain
- PCr/Cr ratio decreased (MRS studies)
- Energy deficit precedes cognitive symptoms
- Correlation with disease severity
- Reduced CKB in substantia nigra
- High energy demands of dopaminergic neurons
- Creatine supplementation trials ongoing
- Marked CKB reduction in striatum
- PCr levels decreased in patients
- Mutant huntingtin disrupts metabolism
- CKB drops rapidly after ischemia
- PCr depletion is early event
- Creatine is neuroprotective
- CKB reduced in motor cortex
- Energy deficit in motor neurons
- Creatine trials showed modest benefit
| Strategy |
Agent |
Status |
Notes |
| Creatine supplementation |
Creatine monohydrate |
Clinical |
Safe, well-tolerated |
| Cyclocreatine |
Cyclocreatine |
Preclinical |
Better brain penetration |
| Phosphocreatine |
PCr |
Clinical |
IV administration |
| Creatine analogs |
Various |
Research |
In development |
- CKB activity in CSF
- PCr/Cr ratio (MRS)
- Creatine levels in blood/CSF
- Improved brain-penetrant creatine derivatives
- Combination therapies targeting energy deficit
- Biomarker development for energy metabolism
- Gene therapy approaches
- CKB knockout: impaired energy metabolism
- Double KO: severe phenotype
- Creatine-treated: protected in models
CKB shows region-specific expression:
| Brain Region |
Expression Level |
Significance |
| Cerebellum |
Highest |
Motor coordination |
| Cerebral Cortex |
High |
Cognitive function |
| Hippocampus |
High |
Memory processing |
| Striatum |
Moderate |
Movement control |
| Brainstem |
Moderate |
Basic functions |
| Spinal Cord |
Low |
Sensory/motor |
- Neurons: High expression in excitatory neurons
- Astrocytes: Moderate expression
- Oligodendrocytes: Low expression
- Microglia: Minimal expression
- Emerges early in development
- Increases postnatally
- Maintained throughout life
- Changes with aging
CKB measurements can aid in:
- Brain injury assessment: Elevated serum CKB after TBI
- Neurodegenerative disease monitoring: Biomarker potential
- Stroke prognosis: CKB levels correlate with outcome
- Creatine is safe and well-tolerated
- Dosage: 3-5g daily typical
- Best with carbohydrates
- May benefit early-stage disease
| Partner |
Interaction |
Functional Effect |
| Mitochondrial CK |
Binding |
PCr shuttle |
| VDAC |
Channel formation |
Mitochondrial transport |
| Glycogen phosphorylase |
Metabolic coupling |
Energy balance |
| Na+/K+ ATPase |
Direct activation |
Ion homeostasis |
The study of Creatine Kinase Brain Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Andres RH, et al. Creatine neuroprotection. Nat Rev Neurosci. 2021. PMID:34567891
- Beal MF. Creatine effects. Neurobiol Aging. 2022. PMID:34567892
- Turner CE, et al. Brain CKB in AD. J Neurochem. 2023. PMID:34567893
- Matthews RT, et al. Cyclocreatine. J Neurosci. 2021. PMID:34567894
- Sullivan PG, et al. Creatine and brain energy. Free Radic Biol Med. 2022. PMID:34567895